Company
RoosterBio
Your Path to Therapeutic Commercialization
Also known as RoosterBio, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Customers
- government, academia, institution, and industry partners
- Legal name
- RoosterBio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At RoosterBio, we are experts in radically simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) to propel the commercialization of therapeutic technologies. By enabling living cells to become more affordable at the lowest cost per million cells with industry leading quality, we make MSCs easier to access and much simpler to incorporate into product development efforts, leading to rapid acceleration in products coming to market that incorporate these technologies.
Funding snapshot
- Total raised
- $18.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $12M2024-03-08
Funding rounds
- Round, 2024
- $12M2024-03-08, SEC form D sold, 8 investors
- Round, 2017
- $1.2M2017-01-27, SEC form D sold, 1 investor
- Round, 2016
- $5.2M2016-11-23, SEC form D sold, 10 investors
- Round, 2013
- $100K2013-12-31, SEC form D sold, 1 investor
Products
- Other
- Cell & Exosome Media
- Other
- cGMP CliniControl Products
- Other
- Exosomes / Extracellular Vesicles
- Other
- Genetic Engineering Tools
- Other
- Human Primary Cells
- Other
- Process Development & Analytical Services
Loading relationship preview